Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional)

The National Institutes of Health (NIH) is soliciting applications for the Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional) under Funding Opportunity Announcement PAR-22-183. This program supports the initial stages of behavioral intervention development research, focusing on establishing feasibility, refining intervention approaches, and evaluating the preliminary efficacy of treatment strategies. The research should explore behavioral, pharmacological, or integrated interventions addressing drug abuse, adherence to treatment, and related health issues. Specific areas of interest include interventions for (1) drug abuse treatment, including those addressing comorbidities; (2) adherence to drug abuse and addiction treatment regimens; (3) adherence interventions leveraging technology to improve outcomes and sustainability; (4) prevention of HIV acquisition or transmission among individuals in drug treatment; (5) adherence to HIV and addiction medications; and (6) substance misuse and chronic pain treatment. This FOA emphasizes Stage I research, including early-phase clinical trials. Eligible applicants include state, county, and city governments; nonprofits with or without 501(c)(3) status; for-profit organizations, including small businesses; public and private institutions of higher education; tribal organizations and governments; and foreign entities. Additional eligibility extends to Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, faith-based organizations, and other regional entities. Applications are due by March 21, 2025, with a posting date of May 9, 2022, and an update on November 20, 2024. There is no cost-sharing requirement. Interested applicants should refer to NIH’s detailed guidelines for proposal preparation, evaluation criteria, and submission processes.